Tech Company Financing Transactions
Sagimet Biosciences Funding Round
Altium Capital, Ascletis and HM Capital participated in a $80 million funding round for Sagimet Biosciences. The round was announced on 2/17/2021.
Transaction Overview
Company Name
Announced On
2/17/2021
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Funds raised will support the advancement of TVB-2640, an oral, first-in-class fatty acid synthase (FASN) inhibitor, including a planned Phase 2b trial evaluating the impact on histological endpoints.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
155 Bovet Rd. 303
San Mateo, CA 94402
USA
San Mateo, CA 94402
USA
Phone
Website
Email Address
Overview
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
George Kemble
Chief Financial Officer
Dennis Hom
Chief Medical Officer
William McCulloch
VP - R & D
Marie O'Farrell
Browse more venture capital transactions:
Prev: 2/17/2021: Strata Identity venture capital transaction
Next: 2/17/2021: Spark Microsystems venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs